| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
8-K: Regulation FD Disclosure
2 November 12, 2026 Legal Notices The information in this slide deck is current as of November 12, 2026, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed wi... |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Nov 2026 | 10-Q |
| 03 Nov 2026 |
Form 4: Vasconcelles Michael, Director
Granted 44,000 Stock Option (right to buy) · Granted 7,500 Restricted Stock Unit |
| 03 Nov 2026 |
Form 3: Vasconcelles Michael, Director
No securities owned |
| 03 Nov 2026 |
Form 4: Kuriakose Emil, Director
Granted 44,000 Stock Option (right to buy) · Granted 7,500 Restricted Stock Unit |
| 03 Nov 2026 |
Form 3: Kuriakose Emil, Director
No securities owned |
| 03 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
ROCKVILLE, MD, November 3, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced th... |
| 23 Oct 2026 |
8-K: Other Events
2 October 23, 2026 Legal Notices The information in this slide deck is current as of October 23, 2026, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics’ Annual, Quarterly and Current Reports filed with... |
| 22 Oct 2026 | 144 |
| 07 Oct 2026 |
Form 4: Bonvini Ezio, Sr VP, Research & CSO
Received 8,000 shares by exercise or conversion ($20.8K) |
| 21 Sep 2026 | 144 |
| 03 Sep 2026 | S-8 |
| 03 Sep 2026 |
8-K/A: Financial Statements and Exhibits
Effective as of June 30, 2026, MacroGenics, Inc. (the “Company”) completed the previously announced sale (the “Closing”) of certain assets and liabilities related to its GMP manufacturing operations (the "Purchased Assets"), including it... |
| 20 Aug 2026 |
Form 4: Peters Jeffrey Stuart, Senior VP, GC, and Secretary
Sold 31,105 shares ($129K) |
| 19 Aug 2026 | 144 |
| 18 Aug 2026 |
Form 4: Bonvini Ezio, Sr VP, Research & CSO
Received 40,000 shares by exercise or conversion ($104K) |
| 17 Aug 2026 | 144 |
| 14 Aug 2026 | 10-Q |
Loading...